Jeffrey S. Dome

Jeffrey S. Dome

Auto-generated profile, based on publicly available information

Jeffrey S. Dome

The George Washington University School of Medicine and Health Sciences 13 Department of Pediatrics Washington, DC

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JDJeffrey S. Dome
Jeffrey S. Dome
NGNorbert Graf
Norbert Graf
JGJames I. Geller
James I. Geller
CFConrad V. Fernandez
Conrad V. Fernandez
EMElizabeth A. Mullen
Elizabeth A. Mullen
KPKathy Pritchard-Jones
Kathy Pritchard-Jones
Clinical trials in Wilms tumor (WT) have resulted in overall survival rates of greater than 90%. This achievement is especially remarkable because improvements in disease-specific survival have occurred concurrently with a reduction of therapy for large patient subgroups. However, the outcomes for certain patient subgroups, including those with unfavorable histologic and molecular features, bilateral disease, and recurrent disease, remain well below the benchmark survival rate of 90%. Therapy for WT has been advanced in part by an increasingly complex risk-stratification system based on patient age; tumor stage, histology, and volume; response to chemotherapy; and loss of heterozygosity at chromosomes 1p and 16q. A consequence of this system has been the apportionment of patients into such small subgroups that only collaboration between large international WT study groups will support clinical trials that are sufficiently powered to answer challenging questions that move the field forward. This article gives an overview of the Children's Oncology Group and International Society of Pediatric Oncology approaches to WT and focuses on four subgroups (stage IV, initially inoperable, bilateral, and relapsed WT) for which international collaboration is pressing. In addition, biologic insights resulting from collaborative laboratory research are discussed. A coordinated expansion of international collaboration in both clinical trials and laboratory science will provide real opportunity to improve the treatment and outcomes for children with renal tumors on a global level.

19 December 2012 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
JDJeffrey S. Dome
Jeffrey S. Dome
CFConrad V. Fernandez
Conrad V. Fernandez
EMElizabeth A. Mullen
Elizabeth A. Mullen
JKJohn A. Kalapurakal
John A. Kalapurakal
JGJames I. Geller
James I. Geller
OCon behalf of the COG Renal Tumors Committee
on behalf of the COG Renal Tumors Committee

1 June 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DDDavid B. Dix
David B. Dix
NSNita L. Seibel
Nita L. Seibel
YCYueh-Yun Chi
Yueh-Yun Chi
GKGeetika Khanna
Geetika Khanna
EGEric Gratias
Eric Gratias
JDJeffrey S. Dome
Jeffrey S. Dome
Purpose: The National Wilms Tumor Study (NWTS) treatment of favorable histology Wilms tumor with lung metastases was vincristine/dactinomycin/doxorubicin (DD4A) and lung radiation therapy (RT). The AREN0533 study applied a new risk stratification and treatment strategy to improve event-free survival (EFS) while reducing exposure to lung RT. Methods: Patients with favorable histology Wilms tumor and isolated lung metastases showing complete lung nodule response (CR) after 6 weeks of DD4A continued receiving chemotherapy without lung RT. Patients with incomplete response (IR) or loss of heterozygosity at chromosomes 1p/16q received lung RT and four cycles of cyclophosphamide/etoposide in addition to DD4A drugs (Regimen M). AREN0533 was designed to preserve a 4-year EFS of 85% for lung nodule CR and improve 4-year EFS from 75% to 85% for lung nodule IR. Results: Among 292 assessable patients, 133 had CR and 159 had IR. For patients with CR, 4-year EFS and overall survival (OS) estimates were 79.5% (95% CI, 71.2% to 87.8%) and 96.1% (95% CI, 92.1% to 100%), respectively. Expected versus observed event rates were 15% and 20.2% ( P = .052), respectively. For patients with IR, 4-year EFS and OS estimates were 88.5% (95% CI, 81.8% to 95.3%) and 95.4% (95% CI, 90.9% to 99.8%), respectively. Expected versus observed event rates were 25% and 12.2% ( P < .001), respectively. Overall, 4-year EFS and OS were 85.4% (95% CI, 80.5% to 90.2%) and 95.6% (95% CI, 92.8% to 98.4%) compared with 72.5% (95% CI, 66.9% to 78.1%; P < .001) and 84.0% (95% CI, 79.4% to 88.6%; P < .001), respectively, in the predecessor NWTS-5 study. Conclusion: Excellent OS was achieved after omission of primary lung RT in patients with lung nodule CR, although there were more events than expected. EFS was significantly improved, with excellent OS, in patients with lung nodule IR using four cycles of cyclophosphamide/etoposide in addition to DD4A drugs. The overall AREN0533 treatment strategy yielded EFS and OS estimates that were superior to previous studies.

29 December 2020 in Current Opinion in Pediatrics
Verified
Journal Article
Closed access
MNMarie V. Nelson
Marie V. Nelson
MHMarry M. van Den Heuvel-Eibrink
Marry M. van Den Heuvel-Eibrink
NGNorbert Graf
Norbert Graf
JDJeffrey S. Dome
Jeffrey S. Dome
Purpose of review: The treatment of Wilms tumor is one of the great achievements in the field of oncology. One of the key success factors has been improved risk stratification, enabling augmentation or reduction of therapy depending on a patient's risk of relapse. This article highlights the evolution of clinical and biological prognostic markers that have been applied in the treatment of Wilms tumor. Recent findings: Historically, tumor stage and histology were the sole determinants of Wilms tumor treatment. Recent clinical trials conducted by the Children's Oncology Group (COG) and the International Society of Pediatric Oncology (SIOP) Renal Tumor Study Group have expanded the menu of prognostic factors to include histologic and volumetric response to therapy and tumor-specific loss of heterozygosity (LOH) at chromosomes 1p and 16q. Augmentation of therapy has been able to overcome the adverse risk factors. An emerging prognostic marker is chromosome 1q gain, will be incorporated into future clinical trials. Summary: The application of new clinical and biological prognostic factors has created unprecedented ability to tailor therapy for Wilms tumor, accompanied with improved outcomes. Current and future trials will continue to enhance precision medicine for Wilms tumor.

27 May 2020 in Cancer
Verified
Journal Article
Closed access
PDF file
PEPeter F. Ehrlich
Peter F. Ehrlich
YCYueh‐Yun Chi
Yueh‐Yun Chi
MCMurali M. Chintagumpala
Murali M. Chintagumpala
FHFredric A. Hoffer
Fredric A. Hoffer
EPElizabeth J. Perlman
Elizabeth J. Perlman
JDJeffrey S. Dome
Jeffrey S. Dome

1 August 2021 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
JDJeffrey S. Dome
Jeffrey S. Dome
EMElizabeth A. Mullen
Elizabeth A. Mullen
DDDavid B. Dix
David B. Dix
EGEric J. Gratias
Eric J. Gratias
PEPeter F. Ehrlich
Peter F. Ehrlich
CFConrad V. Fernandez
Conrad V. Fernandez
Refinements in surgery, radiation therapy, and chemotherapy since the mid-20th century have resulted in a survival rate exceeding 90% for patients with Wilms tumor (WT). Although this figure is remarkable, a significant proportion of patients continue to have event-free survival (EFS) estimates of <75%, and nearly 25% of survivors experience severe chronic medical conditions. The first-generation Children’s Oncology Group (COG) renal tumor trials (AREN ‘0’), which opened to enrollment in 2006, focused on augmenting treatment regimens for WT subgroups with predicted EFS <75% to 80%, including those with the adverse prognostic marker of combined loss of heterozygosity (LOH) at chromosomes 1p/16q, pulmonary metastasis with incomplete lung nodule response after 6 weeks of chemotherapy, bilateral disease, and anaplastic histology. Conversely, therapy was reduced for patient subgroups with good outcomes and potential for long-term toxicity, such as those with lung metastasis with complete lung nodule response after 6 weeks of chemotherapy. This article summarizes the key findings of the first-generation COG renal tumor studies and their implications for clinical practice.